Insulet Corporation, the company behind the OmniPod tubeless Insulin Management System, announced it has entered into an agreement with Eli Lilly and Company according to which Insulet will develop a new version of the OmniPod insulin pump specifically designed to deliver Eli Lilly’s Humulin R U-500 insulin, (regular U-500 [Concentrated] insulin human injection, USP [rDNA origin]), a concentrated form of insulin used by people with highly insulin resistant type 2 diabetes.
Insulet is partnering with Eli Lilly and Company on the clinical development program to evaluate the safety and efficacy of the combined delivery system.
As the incidence of severe insulin resistance continues to rise, more and more people with type 2 diabetes are requiring significantly higher doses of insulin in order to control their blood glucose. This new version of the OmniPod System would be the first insulin pump designed with specific feature modifications to deliver Humulin® R U-500 insulin. Given the rapid increases in rates of obesity and corresponding increases in daily insulin requirements, the new delivery system, if approved, would represents a significant and growing opportunity for people with highly insulin resistant type 2 diabetes to potentially better manage their disease with such a product.
